Thus, hypothesizing that these limitations have contributed to this inconclusive literature, we sought to prospectively evaluate the relationship between gestational glucose tolerance status and emerging cardiometabolic biomarkers (adiponectin, chemerin, RBP-4, CRP, PAI-1) at both 1- and 3-years postpartum in a well-characterized cohort of women reflecting the full spectrum of gestational dysglycemia and hence a broad range of future risk of T2DM and CVD. This evidence concerns the gene SERPINE1 and type 2 diabetes mellitus.